The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Clopidogrel with or without Omeprazole in Coronary Artery Disease
Open accessAbstract
BACKGROUND: Gastrointestinal complications are an important problem of antithrombotic therapy. Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy. Recently, concerns have been raised about the potential for PPIs to blunt the efficacy of clopidogrel. METHODS: We randomly assigned patients with an indication for dual antiplatelet therapy to receive clopidogrel in combination with either omeprazole or placebo, in addition to aspirin. The primary gastrointestinal end point was a composite of overt or occult bleeding, symptomatic gastroduodenal ulcers or erosions, obstruction, or perforation. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, revascularization, or stroke. The trial was terminated prematurely when the sponsor lost financing. RESULTS: We planned to enroll about 5000 patients; a total of 3873 were randomly assigned and 3761 were included in analyses. In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001). The rate of overt upper gastrointestinal bleeding was also reduced with omeprazole as compared with placebo (hazard ratio, 0.13; 95% CI, 0.03 to 0.56; P = 0.001). A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity. The two groups did not differ significantly in the rate of serious adverse events, though the risk of diarrhea was increased with omeprazole. CONCLUSIONS: Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding. There was no apparent cardiovascular interaction between clopidogrel and omeprazole, but our results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI. (Funded by Cogentus Pharmaceuticals; ClinicalTrials.gov number, NCT00557921.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Self-citationPrasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Self-citation(1996) · The Lancet · doi:10.1016/s0140-6736(96)09457-3 · Cited by 6,503
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Steinhubl, S. R., Berger, P. B., Mann III, J. T., Fry, E. T. A., DeLago, A., Wilmer, C., Topol, E. J., & for the CREDO Investigators (2002) · JAMA · doi:10.1001/jama.288.19.2411 · Cited by 3,078
Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events
Bhatt, D. L., Fox, K. A. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060989 · Cited by 2,837
Self-citationMehta, S. R., Yusuf, S., Peters, R. J., Bertrand, M. E., Lewis, B. S., Natarajan, M. K., Malmberg, K., Rupprecht, H.-J., Zhao, F., Chrolavicius, S., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05701-4 · Cited by 2,809
Mehta, S. R., Yusuf, S., & Peters, R. J. G. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00559-7 · Cited by 2,578
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W., Braunwald, E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809171 · Cited by 2,497
Sabatine, M. S., Cannon, C. P., Gibson, C. M., López-Sendón, J. L., Montalescot, G., Theroux, P., Claeys, M. J., Cools, F., Hill, K. A., Skene, A. M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050522 · Cited by 1,924
Self-citation(2005) · The Lancet · doi:10.1016/s0140-6736(05)67660-x · Cited by 1,858
Genetic Determinants of Response to Clopidogrel and Cardiovascular Events
Simon, T., Verstuyft, C., Mary-Krause, M., Quteineh, L., Drouet, E., Méneveau, N., Steg, P. G., Ferrières, J., Danchin, N., & Becquemont, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808227 · Cited by 1,728
Shuldiner, A. R. (2009) · JAMA · doi:10.1001/jama.2009.1232 · Cited by 1,505
Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin
Gilard, M., Arnaud, B., Cornily, J.-C., Le Gal, G., Lacut, K., Le Calvez, G., Mansourati, J., Mottier, D., Abgrall, J.-F., & Boschat, J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.06.064 · Cited by 1,015
Ho, P. M. (2009) · JAMA · doi:10.1001/jama.2009.261 · Cited by 1,007
Collet, J.-P., Hulot, J.-S., Pena, A., Villard, E., Esteve, J.-B., Silvain, J., Payot, L., Brugier, D., Cayla, G., Beygui, F., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61845-0 · Cited by 967
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel
Juurlink, D. N., Gomes, T., Ko, D. T., Szmitko, P. E., Austin, P. C., Tu, J. V., Henry, D. A., Kopp, A., & Mamdani, M. M. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.082001 · Cited by 766
O'Donoghue, M. L., Braunwald, E., Antman, E. M., Murphy, S. A., Bates, E. R., Rozenman, Y., Michelson, A. D., Hautvast, R. W., Ver Lee, P. N., Close, S. L., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61525-7 · Cited by 725
Self-citationLai, K. C., Lam, S. K., Chu, K. M., Wong, B. C. Y., Hui, W. M., Hu, W. H. C., Lau, G. K. K., Wong, W. M., Yuen, M. F., Chan, A. O. O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012877 · Cited by 646
Lanas, A., Bajador, E., Serrano, P., Fuentes, J., Carreño, S., Guardia, J., Sanz, M., Montoro, M., & Sáinz, R. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009213431202 · Cited by 406
Self-citationEffects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel
Siller-Matula, J. M., Spiel, A. O., Lang, I. M., Kreiner, G., Christ, G., & Jilma, B. (2009) · American Heart Journal · doi:10.1016/j.ahj.2008.09.017 · Cited by 397
Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel
Morath, T., Stegherr, J., Braun, S., Vogt, W., Hadamitzky, M., Schömig, A., Kastrati, A., Beckerath, N. V., & Sibbing, D. (2009) · Thrombosis and Haemostasis · doi:10.1160/th08-12-0808 · Cited by 394
Clinical Aspects of Platelet Inhibitors and Thrombus Formation
Meadows, T. A., & Bhatt, D. L. (2007) · Circulation Research · doi:10.1161/01.res.0000264509.36234.51 · Cited by 351
Self-citationSmall, D. S., Farid, N. A., Payne, C. D., Weerakkody, G. J., Li, Y. G., Brandt, J. T., Salazar, D. E., & Winters, K. J. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008315310 · Cited by 316
Lanas, A., García-Rodríguez, L. A., Arroyo, M. T., Bujanda, L., Gomollón, F., Forné, M., Aleman, S., Nicolas, D., Feu, F., González-Pérez, A., et al. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.01062.x · Cited by 298
Self-citationTaha, A. S., McCloskey, C., Prasad, R., & Bezlyak, V. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61246-0 · Cited by 228
Yeomans, N. D., Lanas, Á., Labenz, J., van Zanten, S. V., van Rensburg, C., Rácz, I. A., Tchernev, K. G., Jr., Karamanolis, D. G., Roda, E., Hawkey, C. J., et al. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01995.x · Cited by 214
Intensifying Platelet Inhibition — Navigating between Scylla and Charybdis
Bhatt, D. L. (2007) · New England Journal of Medicine · doi:10.1056/nejme0706859 · Cited by 179
Self-citationLack of Evidence of a Clopidogrel–Statin Interaction in the CHARISMA Trial
Saw, J., Brennan, D. M., Steinhubl, S. R., Bhatt, D. L., Mak, K.-H., Fox, K., & Topol, E. J. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.01.097 · Cited by 170
Self-citationBhatt, D. L., Scheiman, J., Abraham, N. S., Antman, E. M., Chan, F. K. L., Furberg, C. D., Johnson, D. A., Mahaffey, K. W., Quigley, E. M., Harrington, R. A., et al. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.02216.x · Cited by 165
Self-citationTicagrelor — Is There Need for a New Player in the Antiplatelet-Therapy Field?
Schömig, A. (2009) · New England Journal of Medicine · doi:10.1056/nejme0906549 · Cited by 130
Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial
Moukarbel, G. V., Signorovitch, J., Pfeffer, M., McMurray, J. J. V., White, H. D., Maggioni, A. P., Velazquez, E. J., Califf, R. M., Scheiman, J. M., & Solomon, S. D. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp256 · Cited by 110
Prasugrel in Clinical Practice
Bhatt, D. L. (2009) · New England Journal of Medicine · doi:10.1056/nejmp0806848 · Cited by 89
Self-citationReducing the Risks of Gastrointestinal Bleeding with Antiplatelet Therapies
Cryer, B. (2005) · New England Journal of Medicine · doi:10.1056/nejme048330 · Cited by 51
Self-citationTailoring Antiplatelet Therapy Based on Pharmacogenomics
Bhatt, D. L. (2009) · JAMA · doi:10.1001/jama.2009.1249 · Cited by 42
Self-citationOmeprazole and clopidogrel: Should clinicians be worried?
Depta, J. P., & Bhatt, D. L. (2010) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.77a.09173 · Cited by 35
Self-citationClopidogrel-statin interaction: A mountain or a mole hill?
Steinhubl, S. R., & Akers, W. S. (2006) · American Heart Journal · doi:10.1016/j.ahj.2006.01.001 · Cited by 24
Management of Patients with High Gastrointestinal Risk on Antiplatelet Therapy
Cryer, B. (2009) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2009.03.005 · Cited by 22
Self-citation
Cited by
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Roffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Authors/Task Force Members, Steg, P. G., James, S. K., Atar, D., Badano, L. P., Lundqvist, C. B., Borger, M. A., Di Mario, C., Dickstein, K., Ducrocq, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs215 · Cited by 6,829
2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad191 · Cited by 5,333
WRITING COMMITTEE MEMBERS*, O’Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., et al. (2013) · Circulation · doi:10.1161/cir.0b013e3182742cf6 · Cited by 4,725
Metadata
- Authors
- Bhatt, D. L., Cryer, B. L., Contant, C. F., Cohen, M., Lanas, A., Schnitzer, T. J., Shook, T. L., Lapuerta, P., Goldsmith, M. A., Laine, L., Scirica, B. M., Murphy, S. A., & Cannon, C. P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-11-11
- Volume
- 363
- Issue
- 20
- Pages
- 1909-1917
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2152376036
- Cited by
- 1,240
- References
- 39
- FWCI
- 96.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.